Targeting a neutralizing epitope of HIV envelope Gp120 by immune complex vaccine

Journal of AIDS and Clinical Research

Volumn 3, Issue SPL ISSUE8, 2012, Pages

  Kumar, Rajnish ^a   Visciano, Maria Luisa ^a   Li, Hualin ^a   Hioe, Catarina ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84874217721     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.S8-002     Document Type: Review

References (73)

1. Flynn NM, Forthal DN, Harro CD, Judson FN, Mayer KH, et al. (2005) Placebocontrolled phase 3 trial of a recombinant glycoprotein 120 vaccine to prevent HIV-1 infection. J Infect Dis 191: 654-665.
2. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, et al. (2006) Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 194: 1661-1671.
3. Gray G, Buchbinder S, Duerr A (2010) Overview of STEP and Phambili trial results: two phase IIb test-of-concept studies investigating the efficacy of MRK adenovirus type 5 gag/pol/nef subtype B HIV vaccine. Curr Opin HIV AIDS 5: 357-361.
4. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220.
5. Zolla-Pazner S (2004) Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 4: 199-210.
6. Burton DR, Desrosiers RC, Doms RW, Koff WC, Kwong PD, et al. (2004) HIV vaccine design and the neutralizing antibody problem. Nat Immunol 5: 233-236.
7. Reitter JN, Means RE, Desrosiers RC (1998) A role for carbohydrates in immune evasion in AIDS. Nat Med 4: 679-684.
8. McCaffrey RA, Saunders C, Hensel M, Stamatatos L (2004) N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies. J Virol 78: 3279-3295.
9. Ly A, Stamatatos L (2000) V2 loop glycosylation of the human immunodeficiency virus type1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies. J Virol 74: 6769-6776.
10. Wolk T, Schreiber M (2006) N-Glycans in the gp120 V1/V2 domain of the HIV-1 strain NL4-3 are indispensable for viral infectivity and resistance against antibody neutralization. Med Microbiol Immunol 195: 165-172.
11. Teeraputon S, Louisirirojchanakul S, Auewarakul P (2005) N-linked glycosylation in C2 region of HIV-1 envelope reduces sensitivity to neutralizing antibodies. Viral Immunol 8: 343-353.
12. Quinones-Kochs MI, Buonocore L, Rose JK (2002) Role of N-linked glycans in a human immunodeficiency virus envelope glycoprotein: effects on protein function and the neutralizing antibody response. J Virol 76: 4199-4211.
13. Li Y, Cleveland B, Klots I, Travis B, Richardson BA, et al. (2008) Removal of a single N-linked glycan in human immunodeficiency virus type 1 gp120 results in an enhanced ability to induce neutralizing antibody responses. J Virol 82: 638-651.
14. Reitter JN, Desrosiers RC (1998) Identification of replication-competent strains of simian immunodeficiency virus lacking multiple attachment sites for N-linked carbohydrates in variable regions 1 and 2 of the surface envelope protein. J Virol 72: 5399-5407.
15. Reynard F, Fatmi A, Verrier B, Bedin F (2004) HIV-1 acute infection env glycomutants designed from 3D model: effects on processing, antigenicity, and neutralization sensitivity. Virology 324: 90-102.
16. Wu Z, Kayman SC, Honnen W, Revesz K, Chen H, et al. (1995) Characterization of neutralization epitopes in the V2 region of human immunodeficiency virus type 1 gp120: role of glycosylation in the correct folding of the V1/V2 domain. J Virol 69: 2271-2278.
17. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, et al. (2002) HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420: 678-682.
18. Li B, Decker JM, Johnson RW, Bibollet-Ruche F, Wei X, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type1. J Virol 80: 5211-5218.
19. Richman DD, Wrin T, Little SJ, Petropoulos CJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A 100: 4144-4149.
20. Sather DN, Armann J, Ching LK, Mavrantoni A, Sellhorn G, et al. (2009) Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J Virol 83: 757-769.
21. Levesque MC, Moody MA, Hwang KK, Marshall DJ, Whitesides JF, et al. (2009) Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection. PLoS Med 6: e1000107.
22. Zhou T, Georgiev I, Wu X, Yang ZY, Dai K, et al. (2010) Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329: 811-817.
23. Pancera M, McLellan JS, Wu X, Zhu J, Changela A, et al. (2010) Crystal structure of PG16 and chimeric dissection with somatically related PG9: structure-function analysis of two quaternary-specific antibodies that effectively neutralize HIV-1. J Virol 84: 8098-8110.
24. Gray ES, Madiga MC, Hermanus T, Moore PL, Wibmer CK, et al. (2011) The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J Virol 85: 4828-4840.
25. Ng CT, Jaworski JP, Jayaraman P, Sutton WF, Delio P, et al. (2010) Passive neutralizing antibody controls SHIV viremia and enhances B cell responses in infant macaques. Nat Med 16: 1117-1119.
26. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, et al. (2009) Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326: 285-289.
27. Walker LM, Simek MD, Priddy F, Gach JS, Wagner D, et al. (2010) A limited number of antibody specificities mediate broad and potent serum neutralization in selected HIV-1 Infected individuals. PLoS Pathog 6: e1001028.
28. Bonsignori M, Hwang KK, Chen X, Tsao CY, Morris L, et al. (2011) Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol 85: 9998-10009.
29. Wu X, Yang ZY, Li Y, Hogerkorp CM, Schief WR, et al. (2010) Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329: 856-861.
30. Walker LM, Huber M, Doores KJ, Falkowska E, Pejchal R, et al. (2011) Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477: 466-470.
31. Simek MD, Rida W, Priddy FH, Pung P, Carrow E, et al. (2009) Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J Virol 83: 7337-7348.
32. Li Y, Svehla K, Louder MK, Wycuff D, Phogat S, et al. (2009) Analysis of neutralization specificities in polyclonal sera derived from human immunodeficiency virus type 1-infected individuals. J Virol 83: 1045-1059.
33. Heyman B (2000) Regulation of antibody responses via antibodies, complement, and Fc receptors. Annu Rev Immunol 18: 709-737.
34. McCluskie MJ, Wen YM, Di Q, Davis HL (1998) Immunization against hepatitis B virus by mucosal administration of antigen-antibody complexes. Viral Immunol 11: 245-252.
35. Wen YM, Qu D, Zhou SH (1999) Antigen-antibody complex as therapeutic vaccine for viral hepatitis B. Int Rev Immunol 18: 251-258.
36. Ivan J, Velhner M, Ursu K, German P, Mato T, et al. (2005) Delayed vaccine virus replication in chickens vaccinated subcutaneously with an immune complex infectious bursal disease vaccine: quantification of vaccine virus by real-time polymerase chain reaction. Can J Vet Res 69: 135-142.
37. Alber DG, Killington RA, Stokes A (2000) Solid matrix-antibody-antigen complexes incorporating equine herpesvirus 1 glycoproteins C and D elicit anti-viral immune responses in BALB/c (H-2K(d) and C3H (H-2K(k) mice. Vaccine 19: 895-901.
38. Roic B, Cajavec S, Ergotic N, Lipej Z, Madic J, et al. (2006) Immune complexbased vaccine for pig protection against parvovirus. J Vet Med B Infect Dis Vet Public Health 53: 17-23.
39. Rawool DB, Bitsaktsis C, Li Y, Gosselin DR, Lin Y, et al. (2008) Utilization of Fc receptors as a mucosal vaccine strategy against an intracellular bacterium, Francisella tularensis. J Immunol 180: 5548-5557.
40. Hioe CE, Visciano ML, Kumar R, Liu J, Mack EA, et al. (2009) The use of immune complex vaccines to enhance antibody responses against neutralizing epitopes on HIV-1 envelope gp120. Vaccine 28: 352-360.
41. Getahun A, Heyman B (2006) How antibodies act as natural adjuvants. Immunol Lett 104: 38-45.
42. Heyman B (1990) The immune complex: possible ways of regulating the antibody response. Immunol Today 11: 310-313.
43. Jemmerson R, Paterson Y (1986) Mapping epitopes on a protein antigen by the proteolysis of antigen-antibody complexes. Science 232: 1001-1004.
44. Brady LJ, van Tilburg ML, Alford CE, McArthur WP (2000) Monoclonal antibody-mediated modulation of the humoral immune response against mucosally applied Streptococcus mutans. Infect Immun 68: 1796-1805.
45. Oli MW, Rhodin N, McArthur WP, Brady LJ (2004) Redirecting the humoral immune response against Streptococcus mutans antigen P1 with monoclonal antibodies. Infect Immun 72: 6951-6960.
46. Bouige P, Iscaki S, Cosson A, Pillot J (1996) Molecular analysis of the modulatory factors of the response to HBsAg in mice as an approach to HBV vaccine enhancement. FEMS Immunol Med Microbiol 13: 71-79.
47. Denisova G, Stern B, Raviv D, Zwickel J, Smorodinsky NI, et al. (1996) Humoral immune response to immunocomplexed HIV envelope glycoprotein 120. AIDS Res Hum Retroviruses 12: 901-909.
48. Bowman J, Harman C, Manning F, Menticoglou S, Pollock J (1991) Intravenous drug abuse causes Rh immunization. Vox Sang 61: 96-98.
49. Karlsson MC, Wernersson S, Diaz de Stahl T, Gustavsson S, Heyman B (1999) Efficient IgG-mediated suppression of primary antibody responses in Fcgamma receptor-deficient mice. Proc Natl Acad Sci U S A 96: 2244-2249.
50. Quintana IZ, Silveira AV, Moller G (1987) Regulation of the antibody response to sheep erythrocytes by monoclonal IgG antibodies. Eur J Immunol 17: 1343-1349.
51. Myszka DG, Sweet RW, Hensley P, Brigham-Burke M, Kwong PD, et al. (2000) Energetics of the HIV gp120-CD4 binding reaction. Proc Natl Acad Sci U S A 97: 9026-9031.
52. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, et al. (1998) Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393: 648-659.
53. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, et al. (2005) Structure of an unliganded simian immunodeficiency virus gp120 core. Nature 433: 834-841.
54. Liao HX, Alam SM, Mascola JR, Robinson J, Ma B, et al. (2004) Immunogenicity of constrained monoclonal antibody A32-human immunodeficiency virus (HIV) Env gp120 complexes compared to that of recombinant HIV type 1 gp120 envelope glycoproteins. J Virol 78: 5270-5278.
55. Kumar R, Tuen M, Li H, Tse DB, Hioe CE (2011) Improving immunogenicity of HIV-1 envelope gp120 by glycan removal and immune complex formation. Vaccine 29: 9064-9074.
56. Visciano ML, Tuen M, Gorny MK, Hioe CE (2008) In vivo alteration of humoral responses to HIV-1 envelope glycoprotein gp120 by antibodies to the CD4-binding site of gp120. Virology 372: 409-420.
57. Moore JP, Sodroski J (1996) Antibody cross-competition analysis of the human immunodeficiency virus type1 gp120 exterior envelope glycoprotein. J Virol 70: 1863-1872.
58. Ratcliffe A, Stanworth DR (1982) The use of synthetic gamma-chain peptides in the localization of the binding site(s) on human IgG1 for the Fc receptors of homologous monocytes and heterologous mouse macrophages. Immunol Lett 4: 215-221.
59. Ratcliffe A, Stanworth DR (1983) The localization of the binding site(s) on human IgG1 for the Fc receptors on homologous monocytes and heterologous mouse macrophages. Immunology 50: 93-100.
60. Li H, Chien PC Jr, Tuen M, Visciano ML, Cohen S, et al. (2008) Identification of an N-linked glycosylation in the C4 region of HIV-1 envelope gp120 that is critical for recognition of neighboring CD4 T cell epitopes. J Immunol 180: 4011-4021.
61. Li H, Xu CF, Blais S, Wan Q, Zhang HT, et al. (2009) Proximal glycans outside of the epitopes regulate the presentation of HIV-1 envelope gp120 helper epitopes. J Immunol 182: 6369-6378.
62. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, et al. (2010) Anti-V3 monoclonal antibodies display broad neutralizing activities against multiple HIV-1 subtypes. PLoS One 5: e10254.
63. Yu B, Fonseca DP, O'Rourke SM, Berman PW (2010) Protease cleavage sites in HIV-1 gp120 recognized by antigen processing enzymes are conserved and located at receptor binding sites. J Virol 84: 1513-1526.
64. Tuen M, Visciano ML, Chien PC Jr, Cohen S, Chen PD, et al. (2005) Characterization of antibodies that inhibit HIV gp120 antigen processing and presentation. Eur J Immunol 35: 2541-2551.
65. Chien PC Jr, Cohen S, Tuen M, Arthos J, Chen PD, et al. (2004) Human immunodeficiency virus type 1 evades T-helper responses by exploiting antibodies that suppress antigen processing. J Virol 78: 7645-7652.
66. Visciano ML, Tuen M, Chen PD, Hioe CE (2008) Antibodies to the CD4-binding site of HIV-1 gp120 suppress gp120-specific CD4 T cell response while enhancing antibody response. Infect Agent Cancer 3: 11.
67. Hioe CE, Jones GJ, Rees AD, Ratto-Kim S, Birx D, et al. (2000) Anti-CD4-binding domain antibodies complexed with HIV type 1 glycoprotein 120 inhibit CD4+ T cell-proliferative responses to glycoprotein 120. AIDS Res Hum Retroviruses 16: 893-905.
68. Kwissa M, Nakaya HI, Oluoch H, Pulendran B (2012) Distinct TLR adjuvants differentially stimulate systemic and local innate immune responses in nonhuman primates. Blood 119: 2044-2055.
69. Tacken PJ, Zeelenberg IS, Cruz LJ, van Hout-Kuijer MA, van de Glind G, et al. (2011) Targeted delivery of TLR ligands to human and mouse dendritic cells strongly enhances adjuvanticity. Blood 118: 6836-6844.
70. Ferrari G, Pollara J, Kozink D, Harms T, Drinker M, et al. (2011) A HIV-1 gp120 Envelope Human Monoclonal Antibody that Recognizes a C1 Conformational Epitope Mediates Potent ADCC Activity and Defines a Common ADCC epitope in Human HIV-1 Serum. J Virol 85: 7029-7036.
71. Chen L, Kwon YD, Zhou T, Wu X, O'Dell S, et al. (2009) Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science 326: 1123-1127.
72. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, et al. (2007) Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445: 732-737.
73. Emileh A, Abrams CF (2011) A mechanism by which binding of the broadly neutralizing antibody b12 unfolds the inner domain alpha1 helix in an engineered HIV-1 gp120. Proteins 79: 537-546.